BSX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Boston Scientific is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock has just broken down on weak guidance, technicals are bearish, analyst revisions are mostly lower, and there is no proprietary buy signal to override the weakness. The long-term business remains solid, but based on the current data I would not buy it today.
BSX closed at 49.17 after a sharp 12.6% style drawdown recently, with the current market change still showing weakness. The trend is bearish: MACD histogram is below zero and still worsening, and moving averages are stacked bearishly with SMA_200 > SMA_20 > SMA_5. RSI_6 at 20.27 shows the stock is deeply sold off, but not yet a clear reversal signal. Price is trading below the pivot at 53.899 and even near the first support area at 50.041, with next support at 47.657. In short, the trend is down and there is no confirmed technical turnaround yet.
["Barclays kept an Overweight rating and argued the WATCHMAN update is now discounted in the shares.", "Goldman Sachs and other firms still maintain Buy/Outperform-type ratings despite lowering targets.", "Boston Scientific invested $1.5 billion in MiRus, signaling continued expansion ambitions in structural heart/TAVR-adjacent opportunities.", "Congress trading over the last 90 days is balanced overall, with 2 buys and 2 sells, so there is no strong negative political flow."]
["Boston Scientific cut 2026 net sales growth expectations to 7% to 8.5% due to WATCHMAN weakness and competition.", "The stock fell sharply after management reiterated soft growth guidance and weaker demand in key franchises.", "Several analysts cut price targets, and Wells Fargo downgraded the stock to Equal Weight with a much lower target.", "Insiders are selling, and selling activity increased 755.62% over the last month.", "Hedge fund activity is neutral with no significant accumulation trend.", "The stock hit a 52-week low, indicating market sentiment has deteriorated materially."]
No usable latest-quarter financial statement breakdown was provided, so I cannot assess revenue or EPS numerically. The only available fundamental update is management commentary: Boston Scientific lowered 2026 net sales growth expectations to 7% to 8.5% because WATCHMAN growth weakened, and Q2/Q3 WATCHMAN revenue is expected to be sequentially flat rather than growing. That points to slower near-term growth versus prior expectations, even though the company still reiterated overall guidance for Q2 and the full year.
Analyst sentiment is mixed but clearly more cautious than before. Many firms lowered price targets on 2026-05-28 and 2026-05-27, with Goldman Sachs, Leerink, Baird, Citi, Barclays, Stifel, BofA, and Daiwa all revising targets down. The key negative shift was Wells Fargo downgrading BSX to Equal Weight from Overweight. Pros still point to the company’s diversified medtech franchise and some maintained Buy/Outperform ratings. Cons center on WATCHMAN weakness, near-term uncertainty in electrophysiology and cardiac closure, and declining growth estimates. Net: Wall Street is still not uniformly bearish, but the tone has clearly turned more cautious.
